Article
Oncology
Naoyuki Kanayama, Toshiki Ikawa, Shingo Ohira, Takero Hirata, Masahiro Morimoto, Kazuhiko Ogawa, Teruki Teshima, Koji Konishi
Summary: This study demonstrates that a significant reduction in brain metastases volume at 6 months post-SRT can predict local control. The dose of 80% of the gross tumor volume (GTV) D80 in the LQ model: alpha/beta = 20 may be a predictive factor for volume reduction.
Article
Clinical Neurology
Roman O. Kowalchuk, Ajay Niranjan, Judith Hess, Joseph P. Antonios, Michael Y. Zhang, Steve Braunstein, Richard B. Ross, Stylianos Pikis, Christopher P. Deibert, Cheng-chia Lee, Huai-che Yang, Anne-Marie Langlois, David Mathieu, Selcuk Peker, Yavuz Samanci, Chad G. Rusthoven, Veronica Chiang, Zhishuo Wei, L. Dade Lunsford, Daniel M. Trifiletti, Jason P. Sheehan
Summary: This study evaluated the overall survival and local tumor control in a multiinstitutional cohort of patients with triple-negative breast cancer metastases treated with stereotactic radiosurgery (SRS). The findings suggest that SRS is a safe and efficacious treatment for well-selected patients with triple-negative breast cancer who have a favorable performance status and small-to moderate-volume metastatic lesions.
JOURNAL OF NEUROSURGERY
(2023)
Article
Clinical Neurology
William R. Kennedy, Todd A. DeWees, Sahaja Acharya, Mustafaa Mahmood, Nels C. Knutson, S. Murty Goddu, James A. Kavanaugh, Timothy J. Mitchell, Keith M. Rich, Albert H. Kim, Eric C. Leuthardt, Joshua L. Dowling, Gavin P. Dunn, Michael R. Chicoine, Stephanie M. Perkins, Jiayi Huang, Christina I. Tsien, Clifford G. Robinson, Christopher D. Abraham
Summary: This study found that increased internal high-dose volume during SRS treatment for melanoma brain metastases is associated with improved local control without increased toxicity. V30 (volume receiving at least 30 Gy) is an important predictor for LC.
JOURNAL OF NEUROSURGERY
(2021)
Article
Oncology
Laure Kuntz, Clara Le Fevre, Delphine Jarnet, Audrey Keller, Philippe Meyer, Christophe Mazzara, Helene Cebula, Georges Noel, Delphine Antoni
Summary: This retrospective study analyzed the data of patients who received at least two courses of SRT between 2010 and 2020. The results showed that NDFS and OS after SRT were influenced by various factors, including the number of treatments, patient condition, salvage WBRT, and metastasis velocity.
Article
Clinical Neurology
Raj Singh, Greg Bowden, David Mathieu, Haley K. Perlow, Joshua D. Palmer, Shahed Elhamdani, Matthew Shepard, Yun Liang, Ahmed M. Nabeel, Wael A. Reda, Sameh R. Tawadros, Khaled Abdelkarim, Amr M. N. El-Shehaby, Reem M. Emad, Ahmed Hesham Elazzazi, Ronald E. Warnick, Yair M. Gozal, Megan Daly, Brendan McShane, Marcel Addis-Jackson, Gokul Karthikeyan, Sian Smith, Piero Picozzi, Andrea Franzini, Tehila Kaisman-Elbaz, Huai-che Yang, Zhishuo Wei, Andrew Legarreta, Judith Hess, Kelsey Templeton, Stylianos Pikis, Georgios Mantziaris, Gabriela Simonova, Roman Liscak, Selcuk Peker, Yavuz Samanci, Veronica Chiang, Ajay Niranjan, Charles R. Kersh, Cheng-Chia Lee, Daniel M. Trifiletti, L. Dade Lunsford, Jason P. Sheehan
Summary: Limited data is available regarding outcomes for GI primaries patients with brain metastases treated with SRS. This study aimed to examine the clinical outcomes of SRS for patients with brain metastases from GI primaries and evaluate potential prognostic factors. SRS resulted in comparable LC with common primaries. Age and KPS were associated with both LC and OS, and planning target volume and extracranial metastases were correlated with LC and OS, respectively. These factors should be considered in selecting GI cancer patients for SRS.
Article
Clinical Neurology
Daniel D. Cummins, Ramin A. Morshed, Miguel M. Chavez, Lauro N. Avalos, Vivek Sudhakar, Jason E. Chung, Aaron Gallagher, Satvir Saggi, Mariza Daras, Steve Braunstein, Philip Theodosopoulos, Michael W. McDermott, Manish K. Aghi
Summary: Salvage surgery may be effective in controlling brain metastases after previous stereotactic radiosurgery (SRS), especially when combined with adjuvant therapies such as brachytherapy and repeat SRS. Presence of extracranial malignancy is associated with shorter survival.
WORLD NEUROSURGERY
(2022)
Article
Oncology
Mohammed Abdulhaleem, Hannah Johnston, Ralph D'Agostino, Claire Lanier, Michael LeCompte, Christina K. Cramer, Jimmy Ruiz, Thomas Lycan, Hui-Wen Lo, Kuonosuke Watabe, Stacey O'Neill, Christopher Whitlow, Jaclyn J. White, Stephen B. Tatter, Adrian W. Laxton, Jing Su, Michael D. Chan
Summary: This retrospective study compared the clinical outcomes of lung cancer patients receiving immune checkpoint inhibitors and stereotactic radiosurgery with a historical control group. The results showed that patients receiving immunotherapy had improved overall survival and local control compared to the control group.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Camilo E. Fadul, Guneet Sarai, Joseph A. Bovi, Alissa A. Thomas, Wendy Novicoff, Roger Anderson, Ryan F. Amidon, Samantha Schuetz, Rohit Singh, Amy Chang, Ryan D. Gentzler, Elizabeth M. Gaughan, Jason P. Sheehan
Summary: This study aimed to evaluate a prognostic index for predicting survival and treatment benefit in patients with brain metastases. The results suggest that the U-RPA, combined with contemporary treatment options, can provide valuable guidance for patients and clinicians in making treatment decisions.
Article
Oncology
J. A. Crouzen, A. L. Petoukhova, M. L. D. Broekman, M. Fiocco, U. J. Fisscher, J. H. Franssen, C. G. M. Gadellaa-van Hooijdonk, M. Kerkhof, M. Kiderlen, M. E. Mast, C. M. van Rij, R. Nandoe Tewarie, M. A. E. van de Sande, P. P. G. van der Toorn, R. Vlasman, M. J. Vos, N. C. M. G. van der Voort van Zyp, R. G. J. Wiggenraad, L. M. Wiltink, J. D. Zindler
Summary: A multicenter prospective randomized study aims to compare the incidence of adverse local events in patients with brain metastases using fractionated stereotactic radiosurgery (fSRS) versus stereotactic radiosurgery (SRS) in one or three fractions. The study aims to reduce the risk of radionecrosis and improve the effectiveness of brain metastases treatment.
Article
Clinical Neurology
Georgios Mantziaris, Stylianos Pikis, Zhiyuan Xu, Reed Mullen, Juan Alzate, Kenneth Bernstein, Douglas Kondziolka, Zhishuo Wei, Ajay Niranjan, L. Dade Lunsford, Roman Liscak, Jaromir May, Cheng-chia Lee, Huai-che Yang, Francois-Louis Coupe, David Mathieu, Kimball Sheehan, Darrah Sheehan, Joshua D. Palmer, Haley K. Perlow, Selcuk Peker, Yavuz Samanci, Jennifer Peterson, Daniel M. Trifiletti, Matthew J. Shepard, Shahed Elhamdani, Rodney E. Wegner, Herwin Speckter, Wenceslao Hernandez, Ronald E. Warnick, Jason Sheehan
Summary: This retrospective study showed that stereotactic radiosurgery (SRS) is an effective treatment option for intraventricular metastases (IVMs), with a comparable local control rate to SRS for parenchymal brain metastases. However, careful follow-up is needed to detect leptomeningeal spread and hydrocephalus in patients with IVMs.
Review
Oncology
Raees Tonse, Martin C. Tom, Minesh P. Mehta, Manmeet S. Ahluwalia, Rupesh Kotecha
Summary: In modern times, brain metastasis requires multi-modal management and interdisciplinary care. Traditionally, treatment strategies have focused on local treatments alone due to limited efficacy of cytotoxic chemotherapy. However, with the availability of molecular-based therapies with central nervous system penetration, individualized selection of tailored systemic therapies can now be used alongside local treatments. Moreover, the introduction of immune checkpoint inhibitors has further revolutionized the management of brain metastasis patients.
Article
Clinical Neurology
Adomas Bunevicius, Karen Lavezzo, Leah Shabo, Jesse McClure, Jason P. Sheehan
Summary: The study evaluated the quality of life in patients treated with stereotactic radiosurgery for brain metastases, finding that the quality of life remained largely stable post-treatment. Factors such as the patient's RPA class, upfront whole-brain radiation therapy, and the number of intracranial lesions were identified as independent predictors of post-treatment quality of life deterioration. Additionally, a lower pre-treatment quality of life was associated with shorter survival independently of other clinical and demographic variables.
JOURNAL OF NEUROSURGERY
(2021)
Article
Oncology
Slawomir Blamek, Magdalena Stankiewicz, Boguslaw Maciejewski
Summary: The study evaluated the association between physical and biological dose normalized to volume of metastatic tumors, as well as clinical factors, with local control in brain metastases patients treated with robotic stereotactic radiosurgery. It was found that single metastasis, higher total dose, BED10>59 Gy, and absence of extracranial progression were associated with better local control, while BED10/cm(3)>36 Gy and BED2>60 Gy had negative effects. Furthermore, controlling extracranial sites of the disease was linked to higher probability of local control in the brain, particularly in patients with single lesions.
RADIOLOGY AND ONCOLOGY
(2021)
Article
Clinical Neurology
Stylianos Pikis, Adomas Bunevicius, Cheng-Chia Lee, Huai-Che Yang, Brad E. Zacharia, Roman Liscak, Gabriela Simonova, Manjul Tripathi, Narendra Kumar, David Mathieu, Remi Perron, Selcuk Peker, Yavuz Samanci, Jason Gurewitz, Kenneth Bernstein, Douglas Kondziolka, Ajay Niranjan, L. Dade Lunsford, Nikolaos Mantziaris, Jason P. Sheehan
Summary: This multicenter study evaluated the safety and efficacy of stereotactic radiosurgery (SRS) in the management of intracranial prostate cancer metastases. The results showed that SRS was a safe, well-tolerated, and effective treatment option for these patients.
JOURNAL OF NEUROSURGERY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Hesheng Wang, Jinyu Xue, Tanxia Qu, Kenneth Bernstein, Ting Chen, David Barbee, Joshua S. Silverman, Douglas Kondziolka
Summary: Radiomic features from planning MR images and dose maps were used to predict local failure after SRS for brain metastases. A logistic regression model with automatic feature selection achieved a ROC AUC of 0.82 on 5-fold CV, with 83% sensitivity and 70% specificity for predicting local failure. Ten radiomic features significantly associated with treatment outcomes were selected for the model.
Article
Oncology
Tobias Finazzi, Miguel A. Palacios, Femke O. B. Spoelstra, Cornelis J. A. Haasbeek, Anna M. E. Bruynzeel, Ben J. Slotman, Frank J. Lagerwaard, Suresh Senan
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Article
Oncology
Omar Bohoudi, Anna M. E. Bruynzeel, Martijn R. Meijerink, Suresh Senan, Ben J. Slotman, Miguel A. Palacios, Frank J. Lagerwaard
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Oncology
Leonie Alberts, Henri B. Wolff, Elisabeth A. Kastelijn, Frank J. Lagerwaard, Frederik N. Hofman, Sherif Y. El Sharouni, Franz M. N. H. Schramel, Veerle M. H. Coupe
CLINICAL LUNG CANCER
(2019)
Article
Oncology
Anna M. E. Bruynzeel, Shyama U. Tetar, Swie S. Oei, Suresh Senan, Cornelis J. A. Haasbeek, Femke O. B. Spoelstra, Anna H. M. Piet, Philip Meijnen, Marjolein A. B. Bakker van der Jagt, Tamara Fraikin, Berend J. Slotman, Reindert J. A. van Moorselaar, Frank J. Lagerwaard
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Article
Oncology
Niels Verburg, Thomas Koopman, Maqsood M. Yaqub, Otto S. Hoekstra, Adriaan A. Lammertsma, Frederik Barkhof, Petra J. W. Pouwels, Jaap C. Reijneveld, Jan J. Heimans, Annemarie J. M. Rozemuller, Anne M. E. Bruynzeel, Frank Lagerwaard, William P. Vandertop, Ronald Boellaard, Pieter Wesseling, Philip C. de Witt Hamer
Article
Oncology
Jaap Jaspers, Alejandra Mendez Romero, Mischa S. Hoogeman, Martin van den Bent, Ruud G. J. Wiggenraad, Martin J. B. Taphoorn, Danielle B. P. Eekers, Frank J. Lagerwaard, Anna Maria Lucas Calduch, Brigitta G. Baumert, Martin Klein
FRONTIERS IN ONCOLOGY
(2019)
Article
Oncology
Tobias Finazzi, Cornelis J. A. Haasbeek, Femke O. B. Spoelstra, Miguel A. Palacios, Marjan A. Admiraal, Anna M. E. Bruynzeel, Berend J. Slotman, Frank J. Lagerwaard, Suresh Senan
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2020)
Article
Oncology
Henri B. Wolff, Leonie Alberts, Naomi van der Linden, Mathilda L. Bongers, Naomi E. Verstegen, Frank J. Lagerwaard, Frederik N. Hofman, Carin A. Uyl-de Groot, Suresh Senan, Sherif Y. El Sharouni, Elisabeth A. Kastelijn, Franz M. N. H. Schramel, Veerle M. H. Coupe
Article
Oncology
Omar Bohoudi, Frank J. Lagerwaard, Anna M. E. Bruynzeel, Nina Niebuhr, Wibke Johnen, Suresh Senan, Ben J. Slotman, Asja Pfaffenberger, Miguel A. Palacios
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Oncology
Tobias Finazzi, Miguel A. Palacios, Cornelis J. A. Haasbeek, Marjan A. Admiraal, Femke O. B. Spoelstra, Anna M. E. Bruynzeel, Berend J. Slotman, Frank J. Lagerwaard, Suresh Senan
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
Florien W. Boele, Patricia W. M. den Otter, Jaap C. Reijneveld, Philip C. de Witt Hamer, Hinke F. van Thuijl, Linda M. C. Lorenz, Pieter Wesseling, Frank J. Lagerwaard, Martin J. B. Taphoorn, Mathilde C. M. Kouwenhoven, Tom J. Snijders, Linda Douw, Martin Klein
Summary: HRQOL and NCF do not appear greatly impacted during long-term survivorship in LGG, but depressive symptoms and fatigue are persistent.
Article
Oncology
Shyama U. Tetar, Anna M. E. Bruynzeel, Lisa Verweij, Omar Bohoudi, Berend J. Slotman, Tezontl Rosario, Miguel A. Palacios, Frank J. Lagerwaard
Summary: The study showed that daily plan adaptation in magnetic resonance-guided radiotherapy for intermediate- and high-risk prostate cancer can achieve adequate treatment coverage, especially for seminal vesicles.
PHYSICS & IMAGING IN RADIATION ONCOLOGY
(2022)
Review
Oncology
R. Botman, S. U. Tetar, M. A. Palacios, B. J. Slotman, F. J. Lagerwaard, M. E. Bruynzeel
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2019)
Review
Oncology
Anna M. E. Bruynzeel, Frank J. Lagerwaard
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2019)
Article
Oncology
Shyama U. Tetar, Anna M. E. Bruynzeel, Frank J. Lagerwaard, Ben J. Slotman, Omar Bohoudi, Miguel A. Palacios
PHYSICS & IMAGING IN RADIATION ONCOLOGY
(2019)